1 Introduction to Research & Analysis Reports
1.1 Personalized Medicine for Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Personalized Medicine for Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Personalized Medicine for Cancer Overall Market Size
2.1 Global Personalized Medicine for Cancer Market Size: 2022 VS 2029
2.2 Global Personalized Medicine for Cancer Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Personalized Medicine for Cancer Players in Global Market
3.2 Top Global Personalized Medicine for Cancer Companies Ranked by Revenue
3.3 Global Personalized Medicine for Cancer Revenue by Companies
3.4 Top 3 and Top 5 Personalized Medicine for Cancer Companies in Global Market, by Revenue in 2022
3.5 Global Companies Personalized Medicine for Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Personalized Medicine for Cancer Players in Global Market
3.6.1 List of Global Tier 1 Personalized Medicine for Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 Personalized Medicine for Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Personalized Medicine for Cancer Market Size Markets, 2022 & 2029
4.1.2 Immunotherapy
4.1.3 Targeted Therapy
4.1.4 Chemotherapy
4.1.5 Hormone Therapy
4.1.6 Others
4.2 By Type – Global Personalized Medicine for Cancer Revenue & Forecasts
4.2.1 By Type – Global Personalized Medicine for Cancer Revenue, 2018-2023
4.2.2 By Type – Global Personalized Medicine for Cancer Revenue, 2024-2029
4.2.3 By Type – Global Personalized Medicine for Cancer Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Personalized Medicine for Cancer Market Size, 2022 & 2029
5.1.2 Breast Cancer
5.1.3 Blood Cancer
5.1.4 Gastrointestinal Cancer
5.1.5 Prostate Cancer
5.1.6 Skin Cancer
5.1.7 Lung Cancer
5.1.8 Others
5.2 By Application – Global Personalized Medicine for Cancer Revenue & Forecasts
5.2.1 By Application – Global Personalized Medicine for Cancer Revenue, 2018-2023
5.2.2 By Application – Global Personalized Medicine for Cancer Revenue, 2024-2029
5.2.3 By Application – Global Personalized Medicine for Cancer Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Personalized Medicine for Cancer Market Size, 2022 & 2029
6.2 By Region – Global Personalized Medicine for Cancer Revenue & Forecasts
6.2.1 By Region – Global Personalized Medicine for Cancer Revenue, 2018-2023
6.2.2 By Region – Global Personalized Medicine for Cancer Revenue, 2024-2029
6.2.3 By Region – Global Personalized Medicine for Cancer Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Personalized Medicine for Cancer Revenue, 2018-2029
6.3.2 US Personalized Medicine for Cancer Market Size, 2018-2029
6.3.3 Canada Personalized Medicine for Cancer Market Size, 2018-2029
6.3.4 Mexico Personalized Medicine for Cancer Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Personalized Medicine for Cancer Revenue, 2018-2029
6.4.2 Germany Personalized Medicine for Cancer Market Size, 2018-2029
6.4.3 France Personalized Medicine for Cancer Market Size, 2018-2029
6.4.4 U.K. Personalized Medicine for Cancer Market Size, 2018-2029
6.4.5 Italy Personalized Medicine for Cancer Market Size, 2018-2029
6.4.6 Russia Personalized Medicine for Cancer Market Size, 2018-2029
6.4.7 Nordic Countries Personalized Medicine for Cancer Market Size, 2018-2029
6.4.8 Benelux Personalized Medicine for Cancer Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Personalized Medicine for Cancer Revenue, 2018-2029
6.5.2 China Personalized Medicine for Cancer Market Size, 2018-2029
6.5.3 Japan Personalized Medicine for Cancer Market Size, 2018-2029
6.5.4 South Korea Personalized Medicine for Cancer Market Size, 2018-2029
6.5.5 Southeast Asia Personalized Medicine for Cancer Market Size, 2018-2029
6.5.6 India Personalized Medicine for Cancer Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Personalized Medicine for Cancer Revenue, 2018-2029
6.6.2 Brazil Personalized Medicine for Cancer Market Size, 2018-2029
6.6.3 Argentina Personalized Medicine for Cancer Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Personalized Medicine for Cancer Revenue, 2018-2029
6.7.2 Turkey Personalized Medicine for Cancer Market Size, 2018-2029
6.7.3 Israel Personalized Medicine for Cancer Market Size, 2018-2029
6.7.4 Saudi Arabia Personalized Medicine for Cancer Market Size, 2018-2029
6.7.5 UAE Personalized Medicine for Cancer Market Size, 2018-2029
7 Personalized Medicine for Cancer Companies Profiles
7.1 Bayer
7.1.1 Bayer Company Summary
7.1.2 Bayer Business Overview
7.1.3 Bayer Personalized Medicine for Cancer Major Product Offerings
7.1.4 Bayer Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.1.5 Bayer Key News & Latest Developments
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Company Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Personalized Medicine for Cancer Major Product Offerings
7.2.4 GlaxoSmithKline Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.2.5 GlaxoSmithKline Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Personalized Medicine for Cancer Major Product Offerings
7.3.4 Novartis Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 Sanofi
7.4.1 Sanofi Company Summary
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Personalized Medicine for Cancer Major Product Offerings
7.4.4 Sanofi Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.4.5 Sanofi Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Personalized Medicine for Cancer Major Product Offerings
7.5.4 Pfizer Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 Amgen
7.6.1 Amgen Company Summary
7.6.2 Amgen Business Overview
7.6.3 Amgen Personalized Medicine for Cancer Major Product Offerings
7.6.4 Amgen Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.6.5 Amgen Key News & Latest Developments
7.7 Merck
7.7.1 Merck Company Summary
7.7.2 Merck Business Overview
7.7.3 Merck Personalized Medicine for Cancer Major Product Offerings
7.7.4 Merck Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.7.5 Merck Key News & Latest Developments
7.8 Bristol-Myers Squibb
7.8.1 Bristol-Myers Squibb Company Summary
7.8.2 Bristol-Myers Squibb Business Overview
7.8.3 Bristol-Myers Squibb Personalized Medicine for Cancer Major Product Offerings
7.8.4 Bristol-Myers Squibb Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.8.5 Bristol-Myers Squibb Key News & Latest Developments
7.9 Ariad Pharmaceuticals (Takeda)
7.9.1 Ariad Pharmaceuticals (Takeda) Company Summary
7.9.2 Ariad Pharmaceuticals (Takeda) Business Overview
7.9.3 Ariad Pharmaceuticals (Takeda) Personalized Medicine for Cancer Major Product Offerings
7.9.4 Ariad Pharmaceuticals (Takeda) Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.9.5 Ariad Pharmaceuticals (Takeda) Key News & Latest Developments
7.10 Eli Lilly
7.10.1 Eli Lilly Company Summary
7.10.2 Eli Lilly Business Overview
7.10.3 Eli Lilly Personalized Medicine for Cancer Major Product Offerings
7.10.4 Eli Lilly Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.10.5 Eli Lilly Key News & Latest Developments
7.11 Roche
7.11.1 Roche Company Summary
7.11.2 Roche Business Overview
7.11.3 Roche Personalized Medicine for Cancer Major Product Offerings
7.11.4 Roche Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.11.5 Roche Key News & Latest Developments
7.12 Boehringer Ingelheim
7.12.1 Boehringer Ingelheim Company Summary
7.12.2 Boehringer Ingelheim Business Overview
7.12.3 Boehringer Ingelheim Personalized Medicine for Cancer Major Product Offerings
7.12.4 Boehringer Ingelheim Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.12.5 Boehringer Ingelheim Key News & Latest Developments
7.13 Johnson and Johnson
7.13.1 Johnson and Johnson Company Summary
7.13.2 Johnson and Johnson Business Overview
7.13.3 Johnson and Johnson Personalized Medicine for Cancer Major Product Offerings
7.13.4 Johnson and Johnson Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.13.5 Johnson and Johnson Key News & Latest Developments
7.14 Teva Pharmaceuticals
7.14.1 Teva Pharmaceuticals Company Summary
7.14.2 Teva Pharmaceuticals Business Overview
7.14.3 Teva Pharmaceuticals Personalized Medicine for Cancer Major Product Offerings
7.14.4 Teva Pharmaceuticals Personalized Medicine for Cancer Revenue in Global Market (2018-2023)
7.14.5 Teva Pharmaceuticals Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
世界のがん用個別化医療市場予測2023-2029：免疫療法、標的療法、化学療法、ホルモン療法、その他 |
| 【英語タイトル】Personalized Medicine for Cancer Market, Global Outlook and Forecast 2023-2029 | |
 | ・商品コード：MMG23JU5891 ・発行会社（調査会社）：Market Monitor Global ・発行日：2023年6月 ・ページ数：68 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど ・産業分野：医薬品＆医療 |
| Single User（1名様閲覧用） | USD3,250 ⇒換算￥481,000 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD4,225 ⇒換算￥625,300 | 見積依頼/購入/質問フォーム |
| Enterprise User（閲覧人数制限なし） | USD4,875 ⇒換算￥721,500 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 当調査レポートは次の情報を含め、世界のがん用個別化医療市場規模と予測を収録しています。・世界のがん用個別化医療市場：売上、2018年-2023年、2024年-2029年 ・世界のがん用個別化医療市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のがん用個別化医療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「免疫療法」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 がん用個別化医療のグローバル主要企業は、Bayer、 GlaxoSmithKline、 Novartis、 Sanofi、 Pfizer、 Amgen、 Merck、 Bristol-Myers Squibb、 Ariad Pharmaceuticals (Takeda)、 Eli Lilly、 Roche、 Boehringer Ingelheim、 Johnson and Johnson、 Teva Pharmaceuticalsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、がん用個別化医療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のがん用個別化医療市場：タイプ別、2018年-2023年、2024年-2029年 世界のがん用個別化医療市場：タイプ別市場シェア、2022年 ・免疫療法、標的療法、化学療法、ホルモン療法、その他 世界のがん用個別化医療市場：用途別、2018年-2023年、2024年-2029年 世界のがん用個別化医療市場：用途別市場シェア、2022年 ・乳がん、血液がん、消化器がん、前立腺がん、皮膚がん、肺がん、その他 世界のがん用個別化医療市場：地域・国別、2018年-2023年、2024年-2029年 世界のがん用個別化医療市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるがん用個別化医療のグローバル売上、2018年-2023年 ・主要企業におけるがん用個別化医療のグローバル売上シェア、2022年 ・主要企業におけるがん用個別化医療のグローバル販売量、2018年-2023年 ・主要企業におけるがん用個別化医療のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Bayer、 GlaxoSmithKline、 Novartis、 Sanofi、 Pfizer、 Amgen、 Merck、 Bristol-Myers Squibb、 Ariad Pharmaceuticals (Takeda)、 Eli Lilly、 Roche、 Boehringer Ingelheim、 Johnson and Johnson、 Teva Pharmaceuticals ************************************************************* ・調査・分析レポートの概要 がん用個別化医療市場の定義 市場セグメント 世界のがん用個別化医療市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のがん用個別化医療市場規模 世界のがん用個別化医療市場規模：2022年 VS 2029年 世界のがん用個別化医療市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのがん用個別化医療の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のがん用個別化医療製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：免疫療法、標的療法、化学療法、ホルモン療法、その他 がん用個別化医療のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：乳がん、血液がん、消化器がん、前立腺がん、皮膚がん、肺がん、その他 がん用個別化医療の用途別グローバル売上・予測 ・地域別市場分析 地域別がん用個別化医療市場規模 2022年と2029年 地域別がん用個別化医療売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Bayer、 GlaxoSmithKline、 Novartis、 Sanofi、 Pfizer、 Amgen、 Merck、 Bristol-Myers Squibb、 Ariad Pharmaceuticals (Takeda)、 Eli Lilly、 Roche、 Boehringer Ingelheim、 Johnson and Johnson、 Teva Pharmaceuticals ... |
This report aims to provide a comprehensive presentation of the global market for Personalized Medicine for Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Personalized Medicine for Cancer. This report contains market size and forecasts of Personalized Medicine for Cancer in global, including the following market information:
Global Personalized Medicine for Cancer Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Personalized Medicine for Cancer market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Immunotherapy Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Personalized Medicine for Cancer include Bayer, GlaxoSmithKline, Novartis, Sanofi, Pfizer, Amgen, Merck, Bristol-Myers Squibb and Ariad Pharmaceuticals (Takeda), etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Personalized Medicine for Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Personalized Medicine for Cancer Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Personalized Medicine for Cancer Market Segment Percentages, by Type, 2022 (%)
Immunotherapy
Targeted Therapy
Chemotherapy
Hormone Therapy
Others
Global Personalized Medicine for Cancer Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Personalized Medicine for Cancer Market Segment Percentages, by Application, 2022 (%)
Breast Cancer
Blood Cancer
Gastrointestinal Cancer
Prostate Cancer
Skin Cancer
Lung Cancer
Others
Global Personalized Medicine for Cancer Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Personalized Medicine for Cancer Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Personalized Medicine for Cancer revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Personalized Medicine for Cancer revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
GlaxoSmithKline
Novartis
Sanofi
Pfizer
Amgen
Merck
Bristol-Myers Squibb
Ariad Pharmaceuticals (Takeda)
Eli Lilly
Roche
Boehringer Ingelheim
Johnson and Johnson
Teva Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Personalized Medicine for Cancer, market overview.
Chapter 2: Global Personalized Medicine for Cancer market size in revenue.
Chapter 3: Detailed analysis of Personalized Medicine for Cancer company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Personalized Medicine for Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| ★調査レポート[世界のがん用個別化医療市場予測2023-2029：免疫療法、標的療法、化学療法、ホルモン療法、その他] (コード：MMG23JU5891)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界のがん用個別化医療市場予測2023-2029：免疫療法、標的療法、化学療法、ホルモン療法、その他]についてメールでお問い合わせ |
